Чучалин А.Г.(ред.) Пульмонология. Клинические рекомендации
Подождите немного. Документ загружается.
218
Хроническая обструктивная болезнь лёгких
Heart, Lung and Blood Institute, April 2001; NIH Publication No. 2701: 1–
100.
15. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy
for the Diagnosis, Management and Prevention of Chronic Obstructive
Pulmonary Disease. NHLBI/WHO workshop report. – Bethesda, National
Heart, Lung and Blood Institute, April 2001; Update of the Management
Sections, GOLD website (www. goldcopd.com). Date update: 1 Jule 2003.
16. Guyatt G.H., Townsend M., Puqsley S.O. et al. Bronchodilators in chronic
air-flow limitation. Effects on airway function, exercise capacity and quality
of life // Am. Rev. Respir. Dis. – 1987. – Vol. 135. – P. 1069–1074.
17. Ikeda A., Nishimura K., Koyama H. et al. Dose response study of
ipratropium bromide aerosol on maximum exercise performance in stable
patients with chronic obstructive pulmonary disease // Thorax. – 1996. –
Vol. 51. – P. 48–53.
18. Govaert T.M., Thijs C.T., Masurel N. et al. The efficacy of influenza
vaccination in elderly individuals. A randomized double-blind placebo-controlled
trial // JAMA. – 1994. – Vol. 272. – P. 1661–1665.
19. Gross P.A., Quinnan G.V., Rodstein M. et al. Association of influenza
immunization with reduction in mortality in an elderly population. A prospective
study // Arch. Intern. Med. – 1988. – Vol. 148. – P. 562–565.
20. Fedson D.S., Wajda A., Nicol J.P. et al. Clinical effectiveness of influenza
vaccination in Manitoba // JAMA. – 1993. – Vol. 270. – P. 1956–1961.
21. Foster D.A., Talsma A., Furumoto-Dawson A. et al. Influenza vaccine
effectiveness in preventing hospitalization for pneumonia in the elderly //
Am. J. Epidemiol. – 1992. – Vol. 136. – P. 296–307.
22. Nichol K.L., Margolis K.L., Wuorenma J., Von Sternberg T. The efficacy
and cost effectiveness of vaccination against influenza among elderly persons
living in the community // N. Engl. J. Med. – 1994. – Vol. 331. – P. 778–
784.
23. Prevention and control of influenza: recommendations of the Advisory
Committee on Immunization Practices (ACIP) // MMWR Recomm. Rep. –
1997. – Vol. 46. – P. 1–25.
24. van Schayck C.P., Folgering H., Harbers H. et al. Effects of allergy and
age on responses to salbutamol and ipratropium bromide in moderate asthma
and chronic bronchitis // Thorax. – 1991. – Vol. 46. – P. 355–359.
25. Sestini P. et al. Short-acting b
2
-agonistd for stable COPD (Cochran
Review) // The Cochrane Library. – Oxford: Update Software, 2001. –
Issue 4.
26. Standards for the diagnosis and care of patients with chronic obstructive
pulmonary disease. American Thoracic Society // Am. J. Respir. Crit. Care
Med. – 1995. – Vol. 152. – P. S77–121.
27. Siafakas N.M., Vermeire P., Pride N.B. et al. Optimal assessment and
management of chronic obstructive pulmonary disease (COPD). The European
219
Хроническая обструктивная болезнь лёгких
Respiratory Society Task Force // Eur. Respir. J. – 1995. – Vol. 8. – P.
1398–1420.
28. Pauwels R.A., Buist A.S., Calverley P.M. et al. Global strategy for the
diagnosis, management, and prevention of chronic obstructive pulmonary
disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease
(GOLD) Workshop summary // Am. J. Respir. Crit. Care Med. – 2001. –
Vol. 163. – P. 1256–1276.
29. Cambach W., Wagenaar R.C., Koelman T.W. et al. The long-term
effects of pulmonary rehabilitation in patients with asthma and chronic
obstructive pulmonary disease: a research synthesis // Arch. Phys. Med.
Rehabil. – 1999. – Vol. 80. – P. 103–111.
30. Rennard S.I., Serby C.W., Ghafouri M. et al. Extended therapy with
ipratropium is associated with improved lung function in patients with COPD.
A retrospective analysis of data from seven clinical trials // Chest. – 1996. –
Vol. 110. – P. 62–70.
31. Tashkin D.P., Ashutosh K., Bleecker E.R. et al. Comparison of the
anticholinergic bronchodilator ipratropium bromide with metaproterenol in
chronic obstructive pulmonary disease. A 90-day multi-center study // Am.
J. Med. – 1986. – Vol. 81. – P. 81–90.
32. Barnes P. The pharmacological properties of tiotropium // Chest. –
2000. – Vol. 117. – P. S63–69.
33. Littner M.R., Auerbach D., Campbell S. et al. The bronchodilator effects
of tiotropium in stable COPD // Am. J. Respir. Crit. Care Med. – 1997. –
Vol. 155. – P. A282.
34. Littner M.R., Illowite J.S., Tashkin D.P. et al. Long-acting bronchodilation
with once–daily dosing of tiotropium (Spiriva) in stable chronic obstructive
pulmonary disease // Ibid. – 2000. – Vol. 161. – P. 1136–1142.
35. Vincken W., van Noord J.A., Greefhorst A.P.M. et al. Improved health
outcomes in patients with COPD during 1 yr’s treatment with tiotropium //
Eur. Respir. J. – 2002. – Vol. 19. – P. 209–216.
36. Donohue J.F., van Noord J.A., Bateman E.D. et al. A 6-month, placebo-
controlled study comparing lung function and health status changes in COPD
patients treated with tiotropium or salmeterol // Chest. – 2002. – Vol. 122. –
P. 47–55.
37. Casaburi R., Mahler D.A., Jones P. W. et al. A long-term evaluation of
once-daily inhaled tiotropium in chronic obstructive pulmonary disease //
Eur. Respir. J. – 2002. – Vol. 19. – P. 217–224.
38. Ulrik C.S. Efficacy of inhaled salmeterol in the management of smokes
with chronic obstructive pulmonary disease: a single center randomized, double
blind, placebo controlled, crossover study // Thorax. – 1995. – Vol. 50. – P.
750–754.
39. Boyd G., Morice A.H., Pounsford J.C. et al. An evaluation of salmeterol
in the treatment of chronic obstructive pulmonary disease (COPD) // Eur.
Respir. J. – 1997. – Vol. 10. – P. 815–821.
220
Хроническая обструктивная болезнь лёгких
40. Rossi A., Kristufec K., Levine B.E. et al. Comparison of the efficacy,
tolerability and safety of formoterol dry powder and oral, slow-release
theophylline in the treatment of COPD // Chest. – 2002. – Vol. 121. – P.
1058–1069.
41. van Noord J.A., de Munck D.A., Bantje T.A. et. al. Long-term treatment
of chronic obstructive pulmonary disease with salmeterol and the additive
effect of ipratropium // Eur. Respir. J. – 2000. – Vol. 15. – P. 878–885.
42. Tashkin D.P., Bleecker E., Braun S. et al. Results of multi сombination
in chronic obstructive pulmonary disease center study of nebulized inhalant
bronchodilator solutions // Am. J. Med. – 1996. – Vol. 100. – P. 62–69.
43. Sichletidis L., Kottakis J., Marcou S. et al. Bronchodilatory responses to
formoterol, ipratropium, and their combination in patients with stable COPD //
Int. J. Clin. Pract. – 1999. – Vol. 53. – P. 185–188.
44. ZuWallack R.L., Mahler D.A., Reilly D. et al. Salmeterol plus theophylline
combination therapy in the treatment of COPD // Respiration. – 2001. –
Vol. 119. – P. 1661–1670.
45. Calverley P.M., Pauwels R., Vestbo J. et al. Combined salmeterol and
fluticasone in the chronic obstructive pulmonary disease: a randomized
controlled trial // Lancet. – 2003. – Vol. 361. – P. 449–456.
46. Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone
propionate and salmeterol combination delivered via the diskus device in the
treatment of chronic obstructive pulmonary disease // Am. J. Respir. Crit.
Care Med. – 2002. – Vol. 166, N 8. – P. 1084–1091.
47. Lyseng-Williamson K.A., Keating G. Inhaled salmeterol/fluticasone
propionate combination in chronic obstructive pulmonary disease // Am. J.
Respir. Med. – 2002. – Vol. 1, N 4. – P. 273–283.
48. Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of
budesonide/formoterol in the management of chronic obstructive pulmonary
disease // Eur. Respir. J. – 2003. – Vol. 21. – P. 74–81.
49. Robertson A.S., Gove R.I., Wieland G.A. et al. A double-blind comparison
of oral prednisolone 40 mg/day with inhaled beclomethasone dipropionate 1500
mg/day in patients with adult onset chronic obstructive airways disease // Eur.
J. Respir. Dis. – 1986. – Vol. 69, suppl. 146. – P. 565–569.
50. Weir D.C., Gove R.I., Robertson A.S. et al. Corticosteroid trials in non-
asthmatic chronic airflow obstruction: a comparison of oral prednisolone and
inhaled beclomethasone dipropionate // Thorax. – 1990. – Vol. 45. – P.
112–117.
51. Rice K.L., Rubins J.B., Lebahn F. et al. Withdrawal of chronic systemic
corticosteroids in patients with COPD: a randomized trial // Am. J. Respir.
Crit. Med. – 2000. – Vol. 162. – P. 174–178.
52. Poole P.J., Black P.N. Mucolytic agents for chronic bronchitis or chronic
obstructive pulmonary disease // The Cochrane Library. – Oxford: Update
Software, 2002. – Issue 1. Search date 1999; primary sources Cochrane
Airways Group Register and hand searched references.
221
Хроническая обструктивная болезнь лёгких
53. Grandjean E.M., Berthet P., Ruffmann R. et al. Efficacy of oral long-
term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis
of published double-blind, placebo-controlled clinical trials // Clin. Ther. –
2000. – Vol. 22. – P. 209–221. Search date 1995; primary sources Medline,
hand searches of reference list, and personal contact with two experts.
54. Nichol K.L., Margolis K.L., Wuorenma J., Von Stemberg T. The efficacy
and cost effectiveness of vaccination against influenza among elderly persons
living in the community // N. Engl. J. Med. – 1994. – Vol. 331. – P. 778–
784.
55. Centers for Disease Control and Prevention. Prevention of pneumococcal
disease: recommendations of the Advisory Committee on Immunization
Practices (ACIP) // Morb. Mortal. Wkly Rep. – 1997. – Vol. 46. – P. 1–24.
56. American Thoracic Society. Standards for the diagnosis and care of
patients with chronic obstructive pulmonary disease // Am. J. Respir. Crit.
Care Med. – 1995. – Vol. 152. – P. S77–121.
57. Tarpy S.P., Celli B.R. Long-term oxygen therapy // N. Engl. J. Med. –
1995. – Vol. 333. – P. 710–714.
58. International Consensus Conferences in Intensive Care Medicine:
noninvasive positive pressure ventilation in acute respiratory failure // Am. J.
Respir. Crit. Care Med. – 2001. – Vol. 163. – P. 283–291.
59. Mehran R.J., Deslauriers J. Indications for surgery and patient work-up
for bullectomy // Chest Surg. Clin. N. Am. – 1995. – Vol. 5. – P. 717–734.
60. Geddes D., Davies M., Koyama H. et al. Effect of lung-volume-reduction
surgery in patients with severe emphysema // N. Engl. J. Med. – 2000. –
Vol. 343. – P. 239–245.
61. Hosenpud J.D., Bennett L.E., Keck B.M. The Registry of the intemational
Society for Heart and Lung Transplantation: fifteenth official report-1998 //
J. Heart Lung Transplant. – 1998. – Vol. 17. – P. 656–668.
62. Regueiro C.R., Hamel M.B., Davis R.B. et al. A comparison of generalist
and pulmonologist care for patients hospitalized with severe chronic obstructive
pulmonary disease: resource intensity, hospital costs, and survival. SUPPORT
investigators // Am. J. Med. – 1998. – Vol. 105. – P. 366–372.
63. Berry M.J., Rejeski W.J., Adair N.E., Zaccaro D. Exercise rehabilitation
and chronic obstructive pulmonary disease stage // Am. J. Respir. Crit. Care
Med. – 1999. – Vol. 160. – P. 1248–53.
64. The COPD Guidelines Group of the Standards of Care Committee of
the BTS. BTS guidelines for the management of chronic obstructive pulmonary
disease // Thorax. – 1997. – Vol. 52, suppl. 5. – P. S1–S28.
65. Mahon J.L., Laupacis A., Hodder R.V. et al. Theophylline for irreversible
chronic airflow limitation: a randomized study comparing of 1 trials to standard
practice // Chest. – 1999. – Vol. 115. – P. 38–48.
66. Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in
exacerbations of chronic obstructive disease // Ann. Intern. Med. – 1987. –
P. 106–204.
222
Хроническая обструктивная болезнь лёгких
67. Thompson W.N., Nielson C.P., Carvalho P. et al. Controlled trial of
oral prednisone in outpatients with acute COPD exacerbations // Am. J.
Respir. Crit. Care Med. – 1996. – Vol. 154. – P. 407–412.
68. Davies L., Angus R.M. Calverley P.M. Oral cortico-steroids in patients
admitted to hospital with exacerbations of chronic obstructive pulmonary disease:
a prospective randomized controlled trial // Lancet. – 1999. – Vol. 354. – P.
456–460.
69. Niewoehner D.E., Erbland M.L., Deupree R.H. et al. Effect of systemic
glucocorticoids on exacerbations of chronic obstructive pulmonary disease.
Department of Veterans Affairs Cooperative Study Group // N. Engl. J.
Med. – 1999. – Vol. 340. – P. 1941–1947.
70. Kramer N., Meyer T.J., Mcharg J. et al. Randomized prospective trial
of noninvasive positive pressure ventilation in acute respiratory failure // Am.
J. Respir. Crit. Care Med. – 1995. – Vol. 151. – P. 1799–1806.
71. NICE Guideline №12. Chronic Obstructive Pulmonary Disease.
National clinical guideline on management of chronic obstructive pulmonary
disease in adults in primary and secondary care. Developed by the National
Collaborating Centre for Chronic Conditions. – Thorax, 2004. – Vol. 59,
suppl. 1. – P. 1–232.
72. Сelli B.R., MacNee W. and committee members. Standards for the
diagnosis and treatment of patients with COPD: a summary of the ATS/ERS-
position paper // Eur. Respir. J. – 2004. – Vol. 23 (6). – P. 932–946.
73. Chronic Obstructive Pulmonary Disease. Guideline ATS, ERS 2004.
www.thoracic.org/COPD.
74. Miravitlles M., Guerrero T., Mayordomo C., Sanchez-Agudo L., Nicolu
J., EOLO study group. Factors associated with increased risk of exacerbation
and hospital admission in a cohort of ambulatory COPD patients: a multiple
logistics regression analysis // Respiration. – 2000. – Vol. 67. – P. 495–501.
75. Adams S.G., Melo J., Luther M., Anzueto A. Antibiotics are associated
with lower relapse rates in outpatients with acute exacerbations of COPD //
Chest. – 2000. – Vol. 117. – P. 1345–1352.
76. Miravitles M., Murio C., Guerrero T., Gisbert R. for the DAFNE
Study Group. Pharmacoeconimic evaluation of acute exacerbations of chronic
bronchitis and COPD // Chest. – 2002. – Vol. 121. – P. 1449–1455.
77. Aaron S.D., Vandermheen K.L., Clinch J.J. et al. Measurement of
short-term changes in dyspnea and disease specific quality of life following an
acute COPD exacerbation // Chest. – 2002. – Vol. 121. – P. 688–696.
78. Janson D.I. Anxiety and depression are related to the outcome of
emergency treatment in patients with obstructive pulmonary disease // Chest. –
2002. – Vol. 122. – P. 1633–1637.
223
Предметный указатель
ПРЕДМЕТНЫЙ УКАЗАТЕЛЬ
Абсцесс лёгкого 68
Альвеолит
– аллергический 79
– фиброзирующий 133
–– идиопатический 74
–– криптогенный 74
Асбестоз 134
Астма
– бронхиальная 135,190
– профессиональная 134,34
Биопсия лёгкого 163,77
Бодиплетизмография 15,184
Болезнь
– Бека 160
– хроническая обструктивная 171
Бронхит острый 129
Вакцина
– гриппозная 51,198
– пневмококковая 50
Гипертензия артериальная лёгочная 84
Диспноэ 37
Исследование респираторной функции 1
– диффузионная способность 18
– объёмы 2,11
– объёмы и потоки 2
– потоки 2
– спирометрия 2
224
Предметный указатель
Коклюш 136,138
Лёгкое фермера 134
Лёгочное сердце 202
Одышка 37,175
– лечение 46
– оценка 39,176
– типы 44
Пикфлоуметрия 184
Плевральный выпот 68
Плеврит 135,68
Плевродез 155
Пневмония внебольничная 50
Пневмоторакс 144
Респираторная поддержка 48,72
Респираторное исследование 2
Респираторный дистресс-синдром 70
Рефлюкс гастроэзофагеальный 135
Саркоидоз 135,160
Сепсис 70
Синдром
– Блау 164
– воспалительный 174
– респираторного дистресса 70, 156
– Лёфгрена 162,165
– Пертеса–Юнглинга 164
– Мелькерссона 164
– обструкции 180
– полицитемический 187
– постназального затёка 135
– Хеерфордта–Вальденстрёма 162
– Хаммена–Рича 79
Спирометрия 2,182
Тест
– бронходилатационный 10,182
– бронхопровокационный 28
225
Предметный указатель
– ингаляционный
–– бронхоконстрикторный 28
–– бронхопровокационный 27
–– провокационный 27
– метахолиновый 32
– с 6-минутной ходьбой 188,214
Туберкулёз 58,191
Фиброз лёгочный идиопатический 74
Шкала
– 5-балльная 39,212
– визуальная аналоговая 39
– Борга 41
– Borg 41
– Medical Research Council 39
– MRC 39,213
– SCORE 215
– VAS 39